West Pharmaceutical Services, Inc. $WST Shares Bought by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 56.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,600 shares of the medical instruments supplier’s stock after acquiring an additional 10,990 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in West Pharmaceutical Services were worth $7,670,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Holocene Advisors LP acquired a new position in shares of West Pharmaceutical Services in the 3rd quarter worth approximately $49,085,000. Nordea Investment Management AB lifted its position in shares of West Pharmaceutical Services by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 14,950 shares of the medical instruments supplier’s stock valued at $4,122,000 after acquiring an additional 4,477 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of West Pharmaceutical Services by 7.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 236,963 shares of the medical instruments supplier’s stock worth $62,163,000 after acquiring an additional 16,919 shares in the last quarter. Birch Hill Investment Advisors LLC boosted its position in shares of West Pharmaceutical Services by 11.5% in the 4th quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier’s stock valued at $41,862,000 after purchasing an additional 15,678 shares during the period. Finally, Brendel Financial Advisors LLC purchased a new position in West Pharmaceutical Services in the 4th quarter worth about $3,742,000. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This trade represents a 37.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their position. The SEC filing for this sale provides additional information. 0.60% of the stock is currently owned by company insiders.

West Pharmaceutical Services Price Performance

NYSE WST opened at $365.87 on Monday. The company has a market cap of $25.85 billion, a P/E ratio of 48.91, a P/E/G ratio of 3.06 and a beta of 1.16. The company has a fifty day simple moving average of $322.63 and a 200 day simple moving average of $278.92. West Pharmaceutical Services, Inc. has a 1 year low of $206.80 and a 1 year high of $367.66. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to analyst estimates of $779.67 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, sell-side analysts predict that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on WST. Stephens reiterated an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Morgan Stanley upped their target price on West Pharmaceutical Services from $315.00 to $325.00 and gave the company an “equal weight” rating in a report on Friday, May 29th. Citigroup restated a “buy” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $343.73.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.